BWM
ELVN icon

Baystate Wealth Management’s Enliven Therapeutics ELVN Stock Holding History

Baystate Wealth Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$692 Hold
50
– – ﹤0.01% 1182
2023
Q3 		$683 Hold
50
– – ﹤0.01% 919
2023
Q2 		$1.02K Hold
50
– – ﹤0.01% 930
2023
Q1 		$1.09K Buy
+50
New +$1.02K ﹤0.01% 921

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baystate Wealth Management's ELVN Position: Q4 2023 in Review

Baystate Wealth Management held its Enliven Therapeutics (ELVN) position steady in Q4 2023 at 50 shares worth $692. The position accounts for ﹤0.01% of the portfolio, ranked #1182.

Baystate Wealth Management first reported a position in ELVN in Q1 2023 and has held it in 4 quarters since. The position peaked at $1.09K in Q1 2023. 62 funds tracked by Wall St. Rank hold ELVN as of Q4 2023.

  • Baystate Wealth Management held 50 shares of Enliven Therapeutics worth $692 as of Q4 2023.
  • Baystate Wealth Management left its Enliven Therapeutics share count unchanged in Q4 2023.
  • Enliven Therapeutics made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1182 holding.
  • Baystate Wealth Management first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Baystate Wealth Management's Enliven Therapeutics position peaked at $1.09K in Q1 2023.
  • 62 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.